EyePoint Pharmaceuticals ... (EYPT)
| Bid | 6.45 |
| Market Cap | 451.55M |
| Revenue (ttm) | 43.27M |
| Net Income (ttm) | -130.87M |
| EPS (ttm) | -2.32 |
| PE Ratio (ttm) | -2.83 |
| Forward PE | -2.35 |
| Analyst | Buy |
| Ask | 7.3 |
| Volume | 437,458 |
| Avg. Volume (20D) | 862,114 |
| Open | 6.58 |
| Previous Close | 6.71 |
| Day's Range | 6.45 - 6.70 |
| 52-Week Range | 3.91 - 21.26 |
| Beta | 1.41 |
About EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting...
Analyst Forecast
According to 8 analyst ratings, the average rating for EYPT stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 341.40% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call TranscriptEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - ...
2 months ago · seekingalpha.com
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea RivalEyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ongoin...